More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$305534058
EPS
0.54
P/E ratio
12
Price to sales
5.37
Dividend yield
--
Beta
0.564745
Previous close
$8.06
Today's open
$8.08
Day's range
$7.93 - $8.22
52 week range
$4.20 - $9.34
show more
CEO
Kevin J. Knopp
Employees
246
Headquarters
Burlington, MA
Exchange
NASDAQ Global Market
Shares outstanding
37813621
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
908 Devices Inc. (MASS) Q1 2026 Earnings Call Transcript
908 Devices Inc. (MASS) Q1 2026 Earnings Call Transcript
Seeking Alpha • May 6, 2026

908 Devices Acquires NIRLAB AG, Expanding Its Narcotics Detection Portfolio
BURLINGTON, Mass.--(BUSINESS WIRE)-- #LawEnforcement--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has completed the acquisition of NIRLAB AG, a privately held company based in Lausanne, Switzerland. The company delivers AI-powered, cloud-connected near-infrared (NIR) spectroscopy to perform handheld chemical analysis of narcotics in seconds. This acquisition expands 908 Devices' analytical portfolio and strengthens its leadership in narcot.
Business Wire • May 6, 2026

908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook
BURLINGTON, Mass.--(BUSINESS WIRE)-- #ChemicalID--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2026. “We delivered a strong start to 2026, achieving 14% revenue growth and meaningful margin expansion,” said Kevin J. Knopp, CEO and Co-founder. “We are also excited to announce the acquisition of NIRLAB AG, a strate.
Business Wire • May 6, 2026

908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) came out with a quarterly loss of $0.15 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.22 per share a year ago.
Zacks Investment Research • May 6, 2026

908 Devices to Report First Quarter 2026 Financial Results on May 6, 2026
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the first quarter 2026 before market open on Wednesday, May 6, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” sect.
Business Wire • May 1, 2026

908 Devices Appoints Kola Otitoju as Chief Business & Strategy Officer and Announces an Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces the appointment of Kola Otitoju as its Chief Business & Strategy Officer, a newly created executive position. Mr. Otitoju will oversee product and corporate strategy, business development, mergers and acquisitions, and partnership initiatives as 908 Devices expands its market presence across public health, safety, and defense-tech applications. Mr.
Business Wire • Apr 21, 2026

908 Devices to Present at the Sidoti Small Cap Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that CEO and Co-founder Kevin J. Knopp and CFO Joe Griffith will virtually present and host investor meetings at the Sidoti Small Cap Conference on Wednesday, March 18, 2026. The Company presentation is scheduled to begin at 1:45 p.m. Eastern Time. A live audio webcast of t.
Business Wire • Mar 16, 2026

908 Devices Inc. (MASS) Q4 2025 Earnings Call Transcript
908 Devices Inc. (MASS) Q4 2025 Earnings Call Transcript
Seeking Alpha • Mar 3, 2026

908 Devices Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Revenue Outlook
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter and full year ended December 31, 2025. Q4 2025 and Full Year 2025 Financial Highlights Revenue of $17.4 million for the fourth quarter 2025, increasing 21% compared to the fourth quarter 2024 Revenue of $56.2 million for the full year.
Business Wire • Mar 3, 2026

908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.32 per share a year ago.
Zacks Investment Research • Mar 3, 2026

¹ Disclosures

Open an M1 investment account to buy and sell 908 Devices Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.